Risk factor
Poor trading liquidity
Profitability factor
Undervalued vs peers
About
Vetoquinol S.A. is a prominent veterinary pharmaceutical enterprise dedicated to the innovation, development, and global commercialization of both medicinal and non-medicinal solutions for animal health. Its operations extend across Europe, the Americas, and the Asia Pacific regions. The company's diverse product portfolio addresses crucial therapeutic areas, including mobility, pain management, and inflammation; dermatological care and hygiene; anti-parasitic treatments; udder health; infectious disease control; reproductive solutions; behavior modification; internal medicine; and cardiovascular-renal support. These offerings cater to a wide spectrum of animals, encompassing livestock such as cattle, sheep, pigs, and poultry, alongside companion animals like dogs. Founded in 1933, Vetoquinol S.A. is headquartered in Lure, France, and functions as a subsidiary of Soparfin SCA.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBITDA
Target Price
The average target price of VETO.PA is 92.6 and suggests 27.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i